← Eichor
Study identifier: NCT06581549 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Immune Microenvironment and Gene Expression Profiling in Mesothelioma

Condition: Mesothelioma · Mesotheliomas Pleural · Mesothelioma; Lung  ·  Sponsor: Istituto Oncologico Veneto IRCCS

PhaseN/A
Planned participants220
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis. The main unmet medical need in PPM is the lack of a treatment sequence for affected patients. The advent of immune checkpoint inhibitors has changed the first line treatment of PPM, thanks to the improvement in survival achieved by the combination of ipilimumab and nivolumab that are currently approved for non-epithelioid histology in our Country. PPM is characterized by a large heterogeneity of the genomic landscape, which is mainly characterized by the loss of tumour suppressor genes and mutations in DNA repair genes and by an "altered- suppressed" or "excluded" tumor immune microenvironment (TIME). The goal of this project is to improve the immune-biological and molecular stratification of PPM subgroups that can lead to the identification of different personalized treatment approaches. PPM patients (N=220) will be retrospectively (N=150) and prospectively (N=70) recruited from the coordinator center and 6 participating Italian centers. Treatment-naïve tumor samples will be collected and analyzed by bulk gene expression and spatial whole transcriptome analysis, and by 9-color multiplex immunofluorescence. New targets or actionable pathways potentially emerging from such studies will be finally assessed and validated in patient-derived organoids/xenogra…

This description comes directly from the study's public registry record.

Talk to the study team

Giulia Pasello, MD  ·  0498215608  ·  giulia.pasello@iov.veneto.it

Gian Luca De Salvo, MD  ·  0498215704  ·  clinical.trial@iov.veneto.it

Always discuss trial participation with your own doctor first.

Locations (10)

Istituto Clinico HumanitasRozzano, Milano, ItalyRecruiting
Centro di Riferimento Oncologico (CRO) IRCCSAviano, Pordenone, ItalyRecruiting
Azienda Ospedaliera SS Antonio e Biagio e Cesare ArrigoAlessandria, ItalyRecruiting
Asst Papa Giovanni Xxiii BergamoBergamo, ItalyRecruiting
Ircss Ospedale Policlinico San MartinoGenova, ItalyRecruiting
Asst Grande Ospedale Metropolitano Niguarda-MilanoMilan, ItalyRecruiting
Fondazione Ircss Istituto Nazionale Dei Tumori Di MilanoMilan, ItalyRecruiting
Istituto Oncologico VenetoPadova, ItalyRecruiting
Azienda Ospedaliera-Universitaria di ParmaParma, ItalyRecruiting
Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06581549